Key Details
Price
$3.09Annual ROE
-15.85%Beta
0.09Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Aug 09, 2024Recent annual earnings:
Mar 27, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
May 03, 2024Analyst ratings
Recent major analysts updates
Screeners with CSCI included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced the resignation of Carolyn Egbert from the Board of Directors, effective immediately.
TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, announced the appointment of Pierre Labbé to its board of directors and as Chair of the Company's Audit Committee, effective today, to fill the vacancy created by the resignation of Dennis Turpin, also effective today.
TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today provided an update on the progress of its merger integration with Ceapro Inc. (“Ceapro”), including planned changes to its management team and advancements across its current business.
- Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation - Safety of macimorelin confirmed in the pediatric population TORONTO, ONTARIO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announced the top-line results of its Phase 3 safety and efficacy study AEZS-130-P02 (the "DETECT-trial") evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency ("CGHD"). While top-line data show that macimorelin repeatedly demonstrated its capacity to stimulate growth hormone release as required to perform a growth hormone stimulation test, the primary efficacy endpoint for the DETECT-trial has not been met according to the definitions in the study protocol.
FAQ
- What is the primary business of COSCIENS Biopharma?
- What is the ticker symbol for COSCIENS Biopharma?
- Does COSCIENS Biopharma pay dividends?
- What sector is COSCIENS Biopharma in?
- What industry is COSCIENS Biopharma in?
- What country is COSCIENS Biopharma based in?
- When did COSCIENS Biopharma go public?
- Is COSCIENS Biopharma in the S&P 500?
- Is COSCIENS Biopharma in the NASDAQ 100?
- Is COSCIENS Biopharma in the Dow Jones?
- When was COSCIENS Biopharma's last earnings report?
- When does COSCIENS Biopharma report earnings?